SCHULER JACK W

About SCHULER JACK W

Jack W. Schuler is a seasoned U.S. healthcare and diagnostics executive with a long track record in board governance, operating leadership, and private investment. His most notable recent role is Board Member Emeritus at Biodesix, Inc. He served on the company’s board from June 2008 and, in May 2025, transitioned into an emeritus, non-voting advisory capacity. He has also been affiliated with Soleno Therapeutics, Inc. and Accelerate Diagnostics, Inc., underscoring his sustained involvement with Nasdaq-listed healthcare and diagnostic companies. ([investors.biodesix.com](https://investors.biodesix.com/static-files/3d5caf6d-e06a-4ec4-accc-115037fed85a)) Before becoming a board-level investor and advisor, Mr. Schuler held senior executive roles at Abbott Laboratories from 1972 through 1989, including President and Chief Operating Officer. That background gave him deep operational experience in a highly regulated healthcare environment, with exposure to management, marketing, and enterprise execution at scale. He later played a central governance role at Ventana Medical Systems, Inc., serving as a director from 1991 and as Chairman of the Board from 1995 until Ventana’s acquisition by Roche in 2008. This is one of the defining milestones of his career and a key marker of his influence in the diagnostics industry. ([materials.proxyvote.com](https://materials.proxyvote.com/Approved/00430H/20240315/NOMNP_568802.PDF)) Mr. Schuler is also a founding partner of Crabtree Partners, a private investment firm. His broader board experience includes service at Abbott Laboratories, Medtronic, Stericycle, and Quidel Corp., reflecting a long-standing reputation across medical devices, diagnostics, and healthcare services. Across these roles, he has been associated with strategic oversight, capital discipline, and governance for companies navigating growth, innovation, and complex regulatory requirements. ([materials.proxyvote.com](https://materials.proxyvote.com/Approved/00430H/20240315/NOMNP_568802.PDF)) Among his notable contributions, he helped oversee Ventana through a period of strategic development leading up to its acquisition by Roche. At Biodesix, the company explicitly noted that his emeritus role would allow him to continue providing expertise and guidance in an advisory capacity after his board resignation became effective at the 2025 annual meeting. Overall, Mr. Schuler’s profile is that of an experienced healthcare governance leader with deep expertise in diagnostics, board stewardship, and long-term value creation in public companies. ([investors.biodesix.com](https://investors.biodesix.com/static-files/3d5caf6d-e06a-4ec4-accc-115037fed85a))